The meetings were attended by academic scientists

with expertise in the field of bone health or nutrition, members of regulatory authorities as well as industrialists with interests in health claims relating to bone. The objective of the first day of the meeting was to critically review the current literature in the field of health claims related to bone and to discuss the needs and problems to assert PF-6463922 supplier such claims. The objective of the second day was to reach consensus on scientifically acceptable health claims related to bone and to provide guidelines for the design and the methodology of clinical studies which need to be adopted to assert such health claims. A literature search, using Medline database up to August 2010, was performed using keywords including health claims, nutrition, bone, osteoporosis, clinical

study methodology, surrogate endpoint. A selection of relevant papers Fludarabine chemical structure was made by OB, RR, and JYR. Results The GREES panel considers that clinical data in humans are indispensable, and that health claims cannot be accepted solely on the basis of animal data. However, as discussed below, animal studies can give important information not available in humans and can provide data for the learn more generalization of results obtained in a specific tested population to a larger group. Thus, different levels of heath claims should be considered based both on the endpoint used and on the information provided by animal

studies. Pre-clinical models A variety of invasive and non-invasive techniques can be used to provide relevant endpoints [4, 7], including bioavailability studies, microarray or PCR analysis of modulated genes, histomorphometry, culture of bone forming or bone resorbing cells ex vivo, exposure to primary cell cultures to plasma harvested from treated animals, the chemistry and biochemistry of bone tissue, the assessment of biochemical indices of skeletal turnover in blood and urine, metabolic balance of calcium combined with radioactive calcium Rucaparib kinetics, radiogrammetry of bone radiographs, neutron activation for whole body calcium, dual x-ray absorptiometry (DXA), and the assessment of bone strength [8]. The latter endpoint is considered to be the most relevant in the field of bone health claims. Bone strength reflects both bone density and bone quality. Bone quality depends on bone architecture, mineralization, turnover, and accumulation of microdamage. Therefore, the assessment of bone health would benefit from the measurement of bone strength in vivo. No validated non-invasive tools capable of measuring bone strength in vivo are available to date. However, biomechanical tests of resistance to fracture provide an objective measure of overall bone strength. The three main types of biomechanical tests for bone strength are bending, torsional, and compression tests [9].